Skip to main content
. 2022 May 6;14(9):2311. doi: 10.3390/cancers14092311

Figure 3.

Figure 3

ERβ agonist OSU-ERb-12 suppresses the dedifferentiation of ovarian cancer cells. (A) Schematic diagram of experiments designed to analyze cancer cell dedifferentiation. (B–E) OSU-ERb-12 treatment suppressed the conversion of ALDH− cells to ALDH+ cells. ALDH− cells were sorted from OVCAR3 (B,C) and OVCAR4 (D,E) cells using the ALDEFLUOR assay and further cultured in the presence or absence of OSU-ERb-12 (10 µM) for 7 days. The percentage of ALDH+ cells were further analyzed using the ALDEFLUOR assay with flow cytometry. n = 3, bar: SD, ** p < 0.01.